21 Jan Quintessence division to develop drug tests with NIH grant
Madison, Wis. — QBI Life Sciences said it has received $175,000 from the National Institutes of Health and formed partnerships with UW-Madison and the University of Helsinki, Finland, to develop new drug tests.
QBI, a division of Quintessence Biosciences Inc. in Madison, will be working a way to find early indicators of potentially harmful interactions between different drugs given to the same person.
The grant comes under the NIH’s Roadmap for Medical Research program. Keck UWCCC Small Molecule Screening Center at UW-Madison and the Drug Discovery and Development Technology Center in Helsinki will be working with QBI on the project.
“Achievement of the aims under this grant will lead to assays that quickly identify safety issues of drugs long before their use in people,” said professor F. Michael Hoffman at UW-Madison, in a press release.